Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy
Tóm tắt
Considering the anticoagulant actions of vitamin D, we hypothesize that vitamin D status might affect the required dose of warfarin for maintaining the therapeutic international normalized ratio (INR). In a retrospective single-center cohort study, serum levels of 25-hydroxyvitamin D were assessed for 89 subjects receiving a stable dose of warfarin for 3 months or longer and had a stable INR between 2 and 3.5 for at least three consecutive visits. A warfarin sensitivity index (WSI), defined as the steady-state INR divided by the mean daily warfarin dose, was used for measuring the warfarin dose response. The relation between the serum level of 25-hydroxyvitamin D and WSI value and the difference in the mean WSI value between the subjects with different vitamin D status categories (sufficient, insufficient, and deficient) were assessed. Twenty-one subjects had vitamin D deficiency, 43 had vitamin D insufficiency, and only 25 had normal levels of 25-hydroxyvitamin D. Based on the multiple linear regression analysis, there was a significant but weakly positive correlation between WSI and 25-hydroxyvitamin D serum levels, as the value of WSI increases by almost 0.0027434 for every unit increase in 25-hydroxyvitamin D serum level (p value = 0.041). Using one-way ANOVA analysis, there was a trend in a significant difference between the groups with different vitamin D status categories regarding the mean WSI value (F = 2.95, p value = 0.057), as subjects with sufficient vitamin D state compared to those with vitamin D deficiency had a higher WSI value. Although the study’s limitations limit our ability to draw definite conclusions, the present data suggest that in addition to other traditional factors, vitamin D status might also affect warfarin sensitivity and maintenance dose requirement. However, to more clearly explain this link, further studies with high involvement subjects are required.
Tài liệu tham khảo
Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther. 2021;46(3):560–70.
Wen M-S, Lee MTM. Warfarin pharmacogenetics: new life for an old drug. Acta Cardiol Sin. 2013;29(3):235.
James A, Britt R, Raskino C, Thompson S. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45(8):704–6.
Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, Milligan P, Grice G, Lenzini P, Rettie A. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–31.
Shi C, Yan W, Wang G, Wang F, Li Q, Lin N. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10(12): e0144511.
Kimmel SE. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008;9(5):677–86.
Nielsen PB, Lundbye-Christensen S, van der Male M, Larsen TB. Using a personalized decision support algorithm for dosing in warfarin treatment: a randomised controlled trial. Clin Trials Regul Sci Cardiol. 2017;25:1–6.
Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D: a review. Aust J General Pract. 2008;37(12):1002.
Issa L, Leong G, Eisman J. Molecular mechanism of vitamin D receptor action. Inflamm Res. 1998;47(12):451–75.
Pike JW, Christakos S. Biology and mechanisms of action of the vitamin D hormone. Endocrinol Metab Clin. 2017;46(4):815–43.
Thacher TD, Clarke BL. Vitamin D insufficiency. In: Mayo Clinic Proceedings: 2011: Elsevier; 2011, pp 50–60.
Adams J, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95:471–8.
Wang H, Chen W, Li D, Yin X, Zhang X, Olsen N, Zheng SG. Vitamin D and chronic diseases. Aging Dis. 2017;8(3):346.
Mohammad S, Mishra A, Ashraf MZ. Emerging role of vitamin D and its associated molecules in pathways related to pathogenesis of thrombosis. Biomolecules. 2019;9(11):649.
Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1α, 25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000;102(23):2867–72.
Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1α, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood J Am Soc Hematol. 1998;92(1):160–7.
Maillard C, Berruyer M, Serre CM, Amiral J, Dechavanne M, Delmas PD. Thrombomodulin is synthesized by osteoblasts, stimulated by 1, 25-(OH) 2D3 and activates protein C at their cell membrane. Endocrinology. 1993;133(2):668–74.
Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol. 2006;135(3):392–4.
Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, Javadi MR, Dousti S, Hamishehkar H, Maleki S. The effect of high-dose vitamin D3 on soluble P-selectin and hs-CRP level in patients with venous thromboembolism: a randomized clinical trial. Clin Appl Thromb Hemost. 2016;22(5):483–9.
Blondon M, Biver E, Braillard O, Righini M, Fontana P, Casini A. Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocr Connect. 2019;8(11):1447–54.
Hejazi ME, Modarresi-Ghazani F, Hamishehkar H, Mesgari-Abbasi M, Dousti S, Entezari-Maleki T. The effect of treatment of vitamin D deficiency on the level of P-selectin and hs-CRP in patients with thromboembolism: a pilot randomized clinical trial. J Clin Pharmacol. 2017;57(1):40–7.
Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74(3):215–21.
Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost. 1999;81(03):396–9.
Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother. 2006;40(3):397–401.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.
Mohd S, Sharma S, Mishra A, Ashraf MZ. Vitamin D and its relationship with the pathways related to thrombosis and various diseases. London: IntechOpen; 2021.
Martinez-Moreno JM, Herencia C, Oca AM, Muñoz-Castañeda JR, Rodríguez-Ortiz ME, Díaz-Tocados JM, Peralbo-Santaella E, Camargo A, Canalejo A, Rodriguez M. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. FASEB J. 2016;30(3):1367–76.
Toderici M, de la Morena-Barrio ME, Padilla J, Minano A, Antón AI, Iniesta JA, Herranz MT, Fernández N, Vicente V, Corral J. Identification of regulatory mutations in SERPINC1 affecting vitamin D response elements associated with antithrombin deficiency. PLoS ONE. 2016;11(3): e0152159.
Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. In: Seminars in thrombosis and hemostasis: 1998: Copyright© 1998 by Thieme Medical Publishers, Inc.; 1998, pp 217–26.
Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25.
Weiler H, Isermann B. Thrombomodulin. J Thromb Haemost. 2003;1(7):1515–24.
Equils O, Naiki Y, Shapiro A, Michelsen K, Lu D, Adams J, Jordan S. 1, 25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol. 2006;143(1):58–64.
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8.
Timms P, Mannan N, Hitman G, Noonan K, Mills P, Syndercombe-Court D, Aganna E, Price C, Boucher B. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95(12):787–96.
Xu W, Hu X, Qi X, Zhu R, Li C, Zhu Y, Yin S, Cheng L, Zhu R. Vitamin D ameliorates angiotensin II-induced human endothelial progenitor cell injury via the PPAR-γ/HO-1 pathway. J Vasc Res. 2019;56(1):17–27.
Kim D-H, Meza CA, Clarke H, Kim J-S, Hickner RC. Vitamin D and endothelial function. Nutrients. 2020;12(2):575.
Brewer CL, Michos DE, Reis PJ. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets. 2011;12(1):54–60.
Hammer Y, Soudry A, Levi A, Talmor-Barkan Y, Leshem-Lev D, Singer J, Kornowski R, Lev EI. Effect of vitamin D on endothelial progenitor cells function. PLoS ONE. 2017;12(5): e0178057.
Wu W-X, He D-R. Low vitamin D levels are associated with the development of deep venous thromboembolic events in patients with ischemic stroke. Clin Appl Thrombosis Hemostasis. 2018;24(9_suppl):69S-75S.
Dehghani K, Nowrouzi A, Pourdavood AH, Rahmanian Z. Effect of Vitamin D deficiency in lower extremity and pulmonary venous thromboembolism. Biomed Res Therapy. 2019;6(4):3107–12.
Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard B. 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18 791 participants. J Thromb Haemost. 2013;11(3):423–31.
Ehsanian R, Timmerman MA, Wright JM, McKenna S, Dirlikov B, Crew J. Venous thromboembolism is associated with lack of vitamin D supplementation in patients with spinal cord injury and low vitamin D levels. PM&R. 2019;11(2):125–34.
Gallerani M, Boari B, De Toma D, Salmi R, Manfredini R. Seasonal variation in the occurrence of deep vein thrombosis. Med Sci Monitor. 2004;10(5):CR191–6.
Clauss R, Mayes J, Hilton P, Lawrenson R. The influence of weather and environment on pulmonary embolism: pollutants and fossil fuels. Med Hypotheses. 2005;64(6):1198–201.
Ho J-D, Tsai C-Y, Liou S-W, Tsai RJ-F, Lin H-C. Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol. 2008;145(4):722-728.e723.
Lindqvist P, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? AD-lightful hypothesis. J Thromb Haemost. 2009;7(4):605–10.
Banerjee A, Khemka VK. Augmentation of anticoagulant effect with vitamin D: possible therapeutic target for venous thromboembolism. Int J Hematol Blo Dis. 2017;2(1):1–5.
Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, Farsetti S, Annunziata F, Paudice N, Salvadori M. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol. 2011;75(5):440–50.
Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. Thromb Haemost. 2015;113(05):999–1009.
Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen J-B. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res. 2010;125(5):e210–3.
Elbers LP, Wijnberge M, Meijers JC, Poland DC, Brandjes DP, Fliers E, Gerdes VE. Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. Endocr Connect. 2018;7(2):325–33.
Saliba W, Awad K, Ron G, Elias M. The effect of vitamin D supplementation on thrombin generation assessed by the calibrated automated thrombogram. Clin Appl Thromb Hemost. 2016;22(4):340–5.